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Methylenedloxyphenyl Insecticide
Synergists as Potential Human
Health Hazards
by Michael R. Franklin*
The effects of methylenedioxyphenyl insecticide synergists on human health arise, not
from their intrinsic toxicity which is relatively low, but from their dual effect on the oxida-
*tive detoxication or intoxication processes ofthe body. They are able to inhibit these reac-
tions by two mechanisms. They are substrates for mixed function oxidation and, thus, com-
pete with other xenobiotics for available enzyme, and an intermediate in their metabolism
is able to bind with cytochrome P450 to form an inactive complex which absorbs max-
imally at 455 nm. In addition, they are able to activate xenobiotic metabolism by induction
(the increased synthesis and retention) of microsomal oxidative enzymes. Evidence for
these effects is presented, including spectroscopic and enzyme kinetic data. Correlations
with existingin vivo observations are outlined. The inhibition and induction ofcytochrome
P-450, the central enzyme in the metabolism ofxenobiotics, thus provides the focus for con-
sideration of methylenedioxyphenyl synergists as potential hazards.
During the last twenty years, the use of com-
pounds to promote the toxicity and, thus, the
desired effect ofmany insecticides has considerably
reduced the concentrations of the insecticides that
need to be applied. While this has reduced the en-
vironmental load and human exposure to the toxic
insecticide, the possibility ofuntoward effects from
the synergists themselves ought to be considered.
This brief account illustrates the general mechan-
isms which could give cause for concern, or at least
consideration, when assessing the impact of insec-
ticide synergists on the human population.
An insecticide synergist could be any compound
that potentiates insecticide action and, conse-
quently, any compound inhibiting cytochrome
P-450-dependent oxidative metabolism could
qualify. In actual fact, very few inhibitors have
found practical use as synergists. The most widely
encountered compounds are those having the
general structure I, of which the most extensively
investigated and used is piperonyl butoxide. Many
methylenedioxybenzene derivatives occur
naturally, as illustrated here by safrole and
isosafrole, which occur in oil ofsassafras and from
which most of the synthetic synergists were
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originally developed. The four other most com-
monly encountered synthetic synergists are also
shown: sesamex, tropital, sulfoxide, and propyl
isome. All ofthese are characterized by a long oxy-
gen-containing substituent (R1). The nature of the
side chains (R1 and R2) determines the spectrum of
synergistic activity, certain derivatives only being
effective synergists for a limited number of insec-
ticide classes. However, the common feature
necessary for synergistic activity appears to be the
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April 1976 29methylenedioxy grouping. The metabolism ofthese
methylenedioxybenzene derivatives involves two
principal routes: modification of the side groups
and cleavage of the methylenedioxy ring (1-5).
The relative proportions of each of these reactions
depends upon the animal species and the com-
pound studied. If the side groups are small, they
are often oxidized to the carboxylic acid group and
excreted as conjugated derivatives. The
methylenedioxy grouping is metabolized by oxida-
tion (the exact mechanism ofwhich still remains to
be resolved), which yields the methylene carbon
ultimately as C02. Thisleaves a catechol derivative
as the other metabolite.
From the studies of their metabolism, the ra-
tional basis for the use of methylenedioxybenzene
compounds as insecticide synergists was derived.
The enzyme responsible for the oxidation of the
methylene carbon was similar to that involved in
the oxidative metabolism and detoxication of the
insecticides. Thus, their sparing effect was due to
their mutual competition at cytochrome P-450, the
ubiquitous enzyme responsible for oxidative
metabolism of a vast number offoreign compounds
(6). Thus, it could be seen that synergism would
only occur for those compounds which were exten-
sively inactivated by oxidation. Compounds which
require oxidation to activate them into more potent
insecticides would have their insecticide action
decreased.
Withthis knowledge we mustconsider wherethe
possible human health effects might arise. The
acute toxicity of methylenedioxybenzene deriva-
tives in mammals is relatively low (Table 1) (7-9).
For rats, the LD50 for piperonyl butoxide is about
10 g/kg and about 15 g/lkg for propyl isome (7).
Other commonly used methylenedioxyphenyl syn-
ergists are similarly nontoxic. The smaller the side
chains, such as in safrole and isosafrole, the more
toxic the compound. The parent compound,
methylenedioxybenzene, is quite toxic, having an
LDso ofabout 0.5 g/kg.The compounds also seem to
be relatively innocuous on a chronic basis. Toxicity
Table 1. Acute oral toxicity(LD5o).a
LD.0, mg/kg
Rat Mouse
Propyl isome 15,000
Piperonyl butoxide 10,000
Piperonal 2,700
Dihydrosafrole 2,260 3,700.
Safrole 1,950 2,350
Isosafrole 1,340 2,470
Methylenedioxybenzene 580 1,220
aDataofSarles(7)andHagen(8).
is only seen at relatively high dose levels over ex-
tended periods of time. In line with the acute tox-
icities, the methylenedioxyphenyl compounds with
short side chains seem to be the most detrimental.
Tumors have been reported from safrole and
dihydrosafrole administration (8-10), whereas for
piperonyl butoxide, only liver cell changes and
possibly kidney damage seem to occur (11,12).
Safrole carcinogenesis probably arises from the for-
mation of 1-hydroxysafrole which is formed during
the metabolism of this compound (13). No reports
of teratogenic or mutagenic effects of
methylenedioxyphenyl insecticide synergists have
appeared.
Thus, it would appear that for the commonly
used methylenedioxyphenyl synergists, both on
acute or chronic exposure, there seems to be little
need for concern. In one study (14), a single 50-mg
dose of piperonyl butoxide to humans (equivalent
(mjrmoles HCHO / mg /min)-' /V
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FIGURE 1. Alteration of the inhibitory characteristics of
piperonyl butoxide on ethylmorphine N-demethylation by
preincubation of piperonyl butoxide with microsomes and
NADPH. Hepatic microsomes from phenobarbital-pre-
treated rats were suspended in 50mnM Tris-chloride buffer
(pH 7.4) containing 150nM KCI, 10MM MgCls, 10nM
nicotinamide, 7mM isocitrate and 0.27 units of IDH per ml.
Lineweaver-Burk plots were constructed for ethylmorphine
N-demethylation for incubations performed in the absence
(o - -) and presence (o ) ofpiperonyl butoxide and also
(o-), in the presence ofpiperonyl butoxide which had been
preincubated for 5 min with the microsomes and NADPH.
Environmental Health Perspectives 30to 50 times the heaviest likely daily exposure) pro-
duced no apparent harmful effects. What does
become a matter of concern is the effect that these
compounds have on the metabolism of other com-
pounds in the body. A change in the metabolism of
many other drugs can, depending on the drug, in-
crease or decrease its toxicity. Thus, a normally
nontoxic dose of a drug may then produce toxic
symptoms. Before we examine the mechanism of
such drug interactions, it is as well to consider the
reported in vivo effects of methylenedioxyphenyl
synergists and their interactions with other drugs
and foreign compounds.
Piperonyl butoxide and many other
methylenedioxyphenyl compounds were found to
prolong the sleeping time of barbiturates and
paralysis time of zoxazolamine (15-20). Both of
these compounds are oxidatively metabolized to in-
active products, and the effects seen suggest the in-
hibitory effect of piperonyl butoxide on their
metabolism. Also, as might be expected from their
ability to increase the toxicity of insecticides in in-
sects, they can have the same effect with respect to
insecticides in mammals. The acute toxicity of
freons, griseofulvin and benzopyrene in infant mice
has been shown to be increased by piperonyl butox-
ide (21,22). In the realm of carcinogenesis, several
methylenedioxyphenyl compounds have been im-
plicated as being cocarcinogens. This will depend
upon whether the carcinogenic compound under
consideration or its metabolite is the proximate
carcinogen. If the compound per se is the car-
cinogen, then an inhibition of its oxidative
metabolism to noncarcinogenic metabolites would
increase the chances of a cellular interaction
necessary for initiation of the tumor. If an oxida-
tive metabolite is the active species responsible for
the cellular interaction,then an inhibition ofoxida-
tion would slow the formation of reactive
metabolites, allowing possible clearance of the
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FIGURE 2. Spectral changes produced after addition of
piperonyl butoxide and NADPH to an aerobic suspension of
liver microsomes. Rat liver microsomes (2.8 nmole
cytochrome P-450/mg protein) were suspended in 50knM
Tris-chloride buffer (pH 7.4) containing 150 mM KCI and
10mM MgC12. The suspension was divided equally between
two cuvettes and a baseline of equal light absorbance
established. Piperonyl butoxide was then added to the con-
tents of the sample curvette to a concentration of lmM and
the suspension sonicated to disperse the piperonyl butoxide.
The difference spectrum was then determined (. ). 500,uM
NADPH was then added to the sample cuvette and the
difference spectrum again determined 5 min after NADPH
addition (- -).
gm 193
FIGURE 3. The EPR low spin signal of microsomes incubated
with piperonyl butoxide and NADPH. The EPR first deriva-
tive spectra were obtained from microsomal samples (10 mg
protein/ml) which were incubated with piperonyl butoxide
(3.15mM) and NADPH at 25°C for varying periods of time.
The EPR spectra were monitored at - 172°C. The uppermost
trace was obtained before the addition of NADPH, the next
two after 7.2 and 14.0 min of incubations with 2mM
NADPH. The lower trace was recorded 11.3 min after the
addition of lmM NADPH to an identical incubation. The
Varian E4 EPR spectrometer settings were 12.5 gauss
modulation amplitude and a microwave power setting of 50
mW.
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vcompound from the body by other mechanisms,
leading to a decreased incidence of tumor initia-
tion. Examination ofthe effects ofmethylenedioxy-
phenyl synergists, particularly piperonyl butoxide
in vitro, was then needed to account for observa-
tions seen in vivo. It was found that they inhibited
manymixed-function oxidases (5, 23, 24). Although
the inhibition was mainly competitive, indicating
competition between the drug substrates and
methylenedioxyphenyl compounds for the oxida-
tive enzyme, cytochrome P-450, some investiga-
tions yielded results which showed other than com-
petitive inhibition (16, 25, 26). Closely controlled
studies (27) revealed that piperonyl butoxide did
produce competitive inhibition, but the degree of
inhibition at any single concentration increased
with time. This suggested the formation of an even
more inhibitory product from piperonyl butoxide.
Examination of the kinetics of this inhibition
(Fig. 1) showed competitive inhibition initially (i.e.,
increase in Km with no change in Vmax), but
after conditions conducive to the metabolism of
piperonyl butoxide, the kinetics became noncom-
petitive (i.e., a decrease in Vmax). Thus, piperonyl
butoxide was initially a competitive inhibitor and,
subsequently (after metabolism), noncompetitive.
What was the product that was capable of inhibit-
ing the cytochrome P-450 noncompetitively?
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Spectral examination of the cytochrome P-450
enzyme system (or microsomal suspension)
revealed two relevant perturbations (Fig. 2). The
addition of piperonyl butoxide to microsomes pro-
duced a Type I spectrum (28) similarto most ofthe
compounds which are metabolized by cytochrome
P-450. After incubation of this suspension with
NADPH in the presence of oxygen (i.e., conditions
suitable for piperonyl butoxide metabolism), an ab-
sorbance appeared particularly noticeable in the
455 nm region (29, 30). This was attributed to a
product or intermediate formed during the
metabolism of piperonyl butoxide, combining with
the enzyme, cytochrome P-450, that formed it (30).
Evidence that the 455 nm complex involves
cytochrome P-450 is shown in Figure 3, where
electron paramagnetic resonance spectra of
microsomes are presented. Ferric cytochrome
P-450 shows a low spin signal of heme iron withg
tensor values of2.43, 2.26, and 1.93. Upon addition
of NADPH to normal microsomal suspensions,
very little change in the low spin signal is observed
because the steady state lies in the direction of ox-
idized cytochrome P-450. However, in the presence
ofpiperonyl butoxide, the formation ofthe 455 nm
complex traps the cytochrome P-450 in the ferrous
or reduced state, thus causing a decrease in the low
-
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FIGURE 4. The correlation ofthe low spin EPR signal (g = 2.26)withthe amountofcytochrome P-450existing as the 455 nmcomnplex.
Microsomes from phenobarbital-pretreated rats were incubated (10 mg protein/ml) in 5OmM Tris-chloride buffer (pH 7.4) con-
taining 150mM KCI and 10mM MgC12, 3.15mM piperonyl butoxide (sonicated into a fine suspension) and NADPH as indicated.
After various time intervals samples were removed and frozen in tubes suitable for EPR determinations. Optical determinations
of the 455 nm complex were performed continuously in a 2 mm light path cuvette (attached to the incubation flask). The EPR
low spin signal (g = 2.26) was calculated as the peak-trough height ofthe first derivative spectrum, since no signal broadening
was detected, and presented as % of the low spin signal present in the absence of NADPH.
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FIGURE 5. Correlation between the piperonyl butoxide
metabolite-cytochrome P-450 complex and the inhibition of
ethylmorphine N-demethylation. Hepatic microsomes from
phenobarbital-pretreated rats were suspended at a con-
centration of 2.7 mg protein/ml in 5knM Tris-chloride
buffer, pH 7.4, containing 150(nM KCl, 1(inM MgCl. and
various concentrations of piperonyl butoxide. NADPH
(50,uM) was then added, and after 5 min the absorption
spectrum due to the piperonyl butoxide metabolite-reduced
cytochrome P450 complex was determiped (A OD 455-490
nm). Ethylmorphine (6.85mM) was then added and the sub-
sequent initial rate of ethylmorphine N-demethylation
determined. The ethylmorphine N-demethylase activity in
the absence ofpiperonyl butoxide was 6.8 nmole HCHO/mg
protein/min.
spin signal, shown here as a decrease in the
amplitude of the first derivative spectrum. Ex-
amination oftheg = 2.26, or predominant low-spin
signal, of microsomal samples removed at specific
times during the metabolism ofpiperonyl butoxide
(Fig. 4) revealed that the decrease observed in the
signal amplitude (since there was no signal
broadening) correlated with the amount of 455 nm
complex which was detectable by optical
spectroscopy. This agreement held whenthe experi-
ment was performed with two concentrations of
NADPH. If the 455 nm-absorbing complex was
responsible for the noncompetitive inhibition, then
the extent of piperonyl butoxide inhibition of
mixed-functiQn oxidation after preincubation
should be dependent on the amount ofthe 455 nm
complex formed. To determine this, the amount of
the 455 nm complex formed was measured after 5
min preincubation of microsomes with NADPH
and limited quantities of piperonyl butoxide (Fig.
5). The ethylmorphine demethylation reaction was
then initiated and the degree of inhibition deter.-
mined. The two parameters, 455 nm complex for-
mation and degree ofinhibition, were found to cor-
relatevery well (27). Thus, it now seems possible to
explain the very effective insecticide synergistic ac-
tion of piperonyl butoxide and probably other
methylenedioxybenzene derivaties, not only on an
alternative substrate hypothesis but also on the
theory that metabolism ofthe compound results in
an intermediate which complexes with the
cytochrome P-450 in a ligandlike manner to form a
very stable complex. This prevents the participa-
tion ofcytochrome P-450 in insecticide metabolism.
The question that remains at this point is
whether thisin vitro effect is ofconsequence in vivo
and so could account for the whole animal observa-
tions mentioned earlier. The following observa-
tions (Fig. 6-8) show what happens to the liver
microsomal system for up to 48 hr after treatment
ofthe rats with a single intraperitoneal injection of
piperonyl butoxide at two dose levels (500 and
1000 mg/kg). The microsomal cytochrome b5 con-
centration remained unchanged. The carbon
monoxide detectable cytochrome P-450 undergoes
a biphasic change. First, there was a decrease in
concentration which was followed by an increase.
These changes appear to be dose-dependent, the
higher the dose of piperonyl butoxide, the longer
the decrease and the larger the subsequent in-
crease. The type I and type II binding spectra show
similar biphasic changes. The NADPH-cytochrome
c reductase activity undergoes continuous eleva-
tion. The mixed-function oxidase activities (Fig. 7)
determined as ethylmorphine N-demethylation,p-
nitroanisole 0-demethylation, and the rate of 455
nm complex formation from piperonyl butoxide
correspond to the changes seen in the carbon
monoxide detectable cytochrome P-450; that is, an
inhibition below control values followed by an ac-
tivation.
The second phase, or increase, can be accounted
for by the phenomenon of induction. It has been
known for many years that animals can respond to
exposure to foreign compounds by increasing the
liver enzymes responsible for the metabolism of
these compounds (31). With piperonyl butoxide, as
seen here, this is a graded response, the higher dose
producing the larger induction. The explanation
for the initial decrease can be seen in Figure 8. The
animaltreated withpiperonyl butoxide forms a 455
nm complex which survives the preparation of
microsomal fractions and can be measuredin vitro.
The larger the dose of piperonyl butoxide, the
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FIGURE 6. Changes in microsomal cytochrome content and
enzymic activity following piperonyl butoxide administra-
tion: (left) 500 mg/kg; (right) 1000 mg/kg. Hepatic
microsomes were prepared from male rats sacrificed at 0-48
hr after a single IP injection of piperonyl butoxide.
Cytochrome bs, cytochrome P-450, type I and type III bind-
ing spectra were determined in microsomal suspensions con-
taining 2 mg protein/ml. NADPH-cytochrome c reductase
was determined with microsomes at 0.2 mg protein/ml.
Cytochrome bs was determined with a 200,UM NADH
microsomal difference spectrum, and calculated by using the
wavelength pair 420-409 nm (e = 185/mM-cm). Cytochrome
P-450 was determined with a CO difference spectrum of
dithionite reduced microsomes, using the wavelength pair
450-490 nm (E = 91/mM-cm). The binding spectra were peak
to trough absorbance changes after the addition of 3mM
hexobarbital (type I) or saturating concentrations of aniline
(type II) to microsomal suspensions. NADPH-cytochrome c
reductase was determined using absorbance changes at 550
nm (E = 21/mM-cm). Each point represents one animal; the
hatched area shows ± standard deviation for untreated
animals.
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FIGURE 7. Changes in microsomal mixed-function oxidase ac-
tivities after piperonyl butoxide administration: (left) 500
mg/kg; (right) 1000 mg/kg. Hepatic microsomes were pre-
pared from male rats sacrificed at 0-48 hr after an IP injec-
tion of piperonyl butoxide. All determinations were made
with microsomal suspensions at 2 mg protein/ml in 5OnM
Tris buffer containing 50mM KCI and 10mM MgCl2. p-
Nitroanisole demethylation was determined from con-
tinuous monitoring ofp-nitrophenol formation (in pH 7.85
buffer) at 417 nm. Ethylmorphine demethylation activity
was determined from the colorimetric determination of the
formaldehyde produced. The formation of the 455 nm com-
plex was determined by dual wavelength spectroscopy
(455-490 nm) in the presence of0.63mM piperonyl butoxide
after the addition of400MM NADPH. Each point represents
one animal; the hatched area shows ± standard deviation
for untreated animals.
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FIGURE 8. Relationship between heme and the 455 nm complex
in microsomes after piperonyl butoxide administration:
(left) 500 mg/kg; (right) 1000 mg/kg. Hepatic microsomes
were prepared from male rats sacrificed at 0-48 hr after a
single IP injection of piperonyl butoxide. Total microsomal
heme was determined by using alkaline pyridine (e =
32.4/mM-cm for 557-575 nm). Cytochrome bs and
cytochrome P-450 concentration (Fig. 6) were then
subtracted to give the heme imbalance. Microsomal 455 nm
complex concentration was determined using absorbance
at 455 nm, relative to 490 nm for NADPH reduced versus na-
tive microsomal suspensions. Each point represents one
animal; the hatched area shows the standard deviation for
untreated animals.
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34larger and of longer duration is the presence ofthe
complex. This complex prevents the measurement
of cytochrome P-450 with carbon monoxide, since
the carbon monoxide is unable to displace the
metabolite or intermediate from the cytochrome
P-450 (32). This conclusion is reinforced ifthe total
heme in the microsomes is determined and the
measurable cytochrome P-450 and cytochrome b5
subtracted. The resulting discrepancy or imbalance
(lower traces) parallels the amount of the 455 nm
complex detectable. Thus, the initial decrease in
measurable cytochrome P-450 and the inhibition of
mixed-function oxidation (23, 33, 34) can be ac-
counted for by some ofthe cytochrome P-450 exist-
ing in a complexed and, thus, inactivated form
(with a piperonyl butoxide metabolic intermedi-
ate).
In considering the health aspects of the
methylenedioxyphenyl compounds we, therefore,
have to consider two facets: their ability to inhibit
and their ability to induce. The balance of these
two at the time when the individual is exposed to a
second drug or foreign compound may be critical in
determining the consequence. Also, the relative
stability, or persistence, ofthe inactive cytochrome
P-450 complex (33, 35, 37) raises the possibility of
additive inhibitoryeffects from exposure to the syn-
ergists several days apart.
The investigations, together with the omissions,
that have been directed at determining the possible
health effects of the most commonly encountered
methylenedioxyphenyl compound, piperonyl
butoxide, are shown in Table 2. The most visible
omission is the lack of studies to determine any
pharmacological or toxicological effects when com-
pounds are administered with long time intervals
between them and the piperonyl butoxide exposure.
The majority ofinvestigations have been with com-
pounds which are inactivated by cytochrome
P-450-dependent reactions and thus show in-
creased toxicity or pharmacological effect when
given shortly after piperonyl butoxide, i.e., during
the inhibitory phase. For some compounds, such as
bromobenzene and acetaminophen, the toxicity is
Table 2. Alteration of pharmacological or toxicological effect after exposure to piperonyl butoxide.
Alteration of pharmacological (P) or toxicological (T) effect at the
the following time intervals after piperonyl butoxide exposure
Action of cytochrome P-450
metabolism Short (P-450 inhibition) Long (P-450 induction)
Active --. Inactive Increase Decrease
(Insecticides)
Barbiturates (P)
Zoxazolamine (P)
Antipyrine (P)
Griseofulvin (T)
Freons (T)
Benzopyrene (T) (acute)
Inactive -A. Active Decrease Increase
(Insecticides)
Acetaminophen (T)
Bromobenzene (T)
Table 3. Amines capable of forming metabolic 455 nm complexes.
d- and I-Amphetamine Methamphetamine d- and l-Benzphetamine
4-Chloroamphetamine 4-Chloromethamphetamine
4-Methoxyamphetamine (PMA) Methoxyphenamine SKF 525-A
3,4-Methylenedioxyamphetamine (MDA) Propylhexedrine Lilly 18947
2,3-,2,5-, and 3,5-Dimethoxyamphetamine Cyclopentamine Adiphenine
2,3,4-,3,4,5-,2,4,5-, and 2,4,6-, Trimethoxyamphetamine Fenfluramine Benactyzine
2,5-Dimethoxy-4-bromoamphetamine Phenmetrazine Propoxyphene
2,5-Dimethoxy-4-methylamphetamine (STP) Benzylamphetamine Methadone
2,4-Dimethoxy-5-methylamphetamine N-Hydroxyamphetamine Diphenhydramine
3,4-Ethylenedioxy-5-methoxyamphetamine Propylamphetamine Acetylmethadol
3,4-Methylenedioxy-5-methoxyamphetamine
SKF 26754-A SKF 8742-A
Desipramine
Nortriptyline
Environmental Health Perspectives 35mainly due to metabolites formed during
cytochrome P-450-dependent oxidative reactions
(8, 39). If these compounds are received shortly
after methylenedioxyphenyl exposure, theirtoxicity
is reduced since less of the toxic metabolite will be
formed. However, if the exposure to methylene-
dioxyphenyl compounds had been large and long
enough to cause induction, then the increased
amount ofenzyme will increase the amount oftoxic
metabolite produced and one would, therefore, ex-
pect an increase in toxicity.
In conclusion, it is obvious that much of the
glamorous work concerning piperonyl butoxide
metabolism has been done. However, there are
many areas, perhaps less glamorous, which need
extensive investigation ifwe are to judge the poten-
tial human health hazards ofinsecticide synergists,
in particular, and inhibitors of drug metabolism in
general. The need has become more urgent withthe
discovery that methylenedioxyphenyl synergists
are not the only compounds capable offorming 455
nm complexes with cytochrome P-450 during
metabolism (Table 3). A variety of amines,
especially amphetamine derivatives (40-44), also
form such complexes. We mayfind thatthe study of
insecticide synergists will develop a whole new un-
derstanding of clinical drug interactions which
will, hopefully, reduce health hazards in drug
therapy.
This study was supported in part by USPHS
Grant No. CA 15760.
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